Literature DB >> 17608689

Role of endogenous 4-1BB in the development of systemic lupus erythematosus.

Dass S Vinay1, Jae H Choi, Jung D Kim, Beom K Choi, Byoung S Kwon.   

Abstract

Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies directed against nuclear antigens including nucleosomes and DNA. To determine the role of T-cell costimulatory molecule 4-1BB in the regulation of SLE, MRL-Fas(lpr) (lpr) mice deficient in 4-1BB (lpr/4-1BB(-/-)) were generated and their disease phenotype was compared to that of control lpr mice. The main finding of this study is that the lpr/4-1BB(-/-) mice had more pronounced skin lesions which appeared earlier, increased lymphadenopathy, increased renal damage, and higher mortality than 4-1BB-intact control lpr mice. The increased severity of lesions in lpr/4-1BB(-/-) mice was closely associated with increases in CD4(+) T, CD3(+) B220(+) double-negative T cells, serum immunoglobulin, anti-dsDNA autoantibodies, and tissue immunoglobulin deposits. These data suggest that the 4-1BB-4-1BB ligand signalling pathway plays an important role in SLE and that deletion of 4-1BB confers susceptibility to lpr mice, leading to accelerated induction of disease and early mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608689      PMCID: PMC2266025          DOI: 10.1111/j.1365-2567.2007.02653.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Successful transfer of localized autoimmunity with positively selected CD4+ cells to scid mice lacking functional B cells.

Authors:  K Ohno; T Takahashi; K Maki; M Ueda; O Taguchi
Journal:  Autoimmunity       Date:  1999       Impact factor: 2.815

2.  Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity.

Authors:  P E Lipsky
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

3.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Murine lupus in the absence of alpha beta T cells.

Authors:  S L Peng; M P Madaio; D P Hughes; I N Crispe; M J Owen; L Wen; A C Hayday; J Craft
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

Review 5.  Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.

Authors:  Anna-Marie Fairhurst; Amy E Wandstrat; Edward K Wakeland
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

6.  Enhanced CD4 T cell responsiveness in the absence of 4-1BB.

Authors:  Seung-Woo Lee; Anthony T Vella; Byoung S Kwon; Michael Croft
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

7.  Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level.

Authors:  O T Chan; V Paliwal; J M McNiff; S H Park; A Bendelac; M J Shlomchik
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 8.  Dual immunoregulatory pathways of 4-1BB signaling.

Authors:  Dass S Vinay; Kiweon Cha; Byoung S Kwon
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

9.  Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells.

Authors:  M Murakami; H Yoshioka; T Shirai; T Tsubata; T Honjo
Journal:  Int Immunol       Date:  1995-05       Impact factor: 4.823

Review 10.  Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus.

Authors:  Annett M Jacobi; Betty Diamond
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

View more
  16 in total

Review 1.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 2.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

Review 3.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

4.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

Review 5.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.

Authors:  Ido Somekh; Marini Thian; David Medgyesi; Nesrin Gülez; Thomas Magg; Alejandro Gallón Duque; Tali Stauber; Atar Lev; Ferah Genel; Ekrem Unal; Amos J Simon; Yu Nee Lee; Artem Kalinichenko; Jasmin Dmytrus; Michael J Kraakman; Ginette Schiby; Meino Rohlfs; Jeffrey M Jacobson; Erdener Özer; Ömer Akcal; Raffaele Conca; Türkan Patiroglu; Musa Karakukcu; Alper Ozcan; Tala Shahin; Eliana Appella; Megumi Tatematsu; Catalina Martinez-Jaramillo; Ivan K Chinn; Jordan S Orange; Claudia Milena Trujillo-Vargas; José Luis Franco; Fabian Hauck; Raz Somech; Christoph Klein; Kaan Boztug
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

Review 7.  Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.

Authors:  Dana A Emerson; William L Redmond
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

Review 8.  Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus.

Authors:  Nien Yee Kow; Anselm Mak
Journal:  Clin Dev Immunol       Date:  2013-07-29

Review 9.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

Review 10.  Targeting dendritic cell function during systemic autoimmunity to restore tolerance.

Authors:  Juan P Mackern-Oberti; Fabián Vega; Carolina Llanos; Susan M Bueno; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2014-09-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.